By Dr. Brandon Bright, DAOM, LAc · Doctor of Acupuncture & Oriental Medicine · Functional Medicine University-certified · Tustin, CA · Last reviewed: June 9, 2026
Eli Lilly is preparing to present the headline data from TRIUMPH-1 at the American Diabetes Association Scientific Sessions in mid-June 2026. If you’ve been on Wegovy, Zepbound, Mounjaro, or compounded semaglutide — or if you’ve been waiting to decide — this is the moment to understand what’s about to enter the conversation, what it does and doesn’t mean for you, and how to think about timing. This piece is patient context, not prescribing advice. I’m a DAOM clinician, not a medical doctor. I don’t prescribe these medications. I do help patients in Orange County think through the broader plan, and that’s what this article is for.
The 55-Second Answer
Retatrutide is Lilly’s next-generation weight-loss drug currently in late-stage trials. It’s a “triple agonist” — it activates three metabolic pathways at once (GLP-1, GIP, and glucagon receptors), where Wegovy is a single (GLP-1) and Zepbound is a dual (GLP-1 + GIP). Earlier Phase 2 data showed body-weight reduction in the 24% range over 48 weeks, which is meaningfully higher than the ~21% Zepbound topline. TRIUMPH-1 is the pivotal Phase 3 trial, and the mid-June ADA presentation is the first major public look at the headline efficacy and safety data. FDA approval is expected late 2026 to mid-2027 if the data holds. None of this changes what you should do this week if you’re already on a GLP-1, but it does change how to think about your 18-month plan.
What’s Actually Being Presented at ADA
Eli Lilly’s Phase 3 program for retatrutide includes the TRIUMPH-1 trial for obesity, plus TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4 covering related indications (type 2 diabetes, obesity with cardiovascular risk, and others). The ADA Scientific Sessions in mid-June 2026 are where the obesity Phase 3 data is being unveiled.
What the cardiology, endocrinology, and obesity-medicine communities are watching for:
- Headline weight loss percentage. Phase 2 hit ~24%. If Phase 3 holds at or near that number, retatrutide becomes the most effective weight-loss medication ever brought to market.
- Safety profile. Triple agonism is mechanically aggressive. Side-effect rates around GI tolerability, muscle loss, gallbladder events, and pancreatic markers are being watched carefully.
- Cardiovascular endpoints. Lilly is expected to share interim cardiovascular safety signals.
- Subgroup analysis. Differential response by sex, BMI band, baseline metabolic health, and comorbidities — particularly relevant because women have historically been undersampled in early obesity-medicine trials.
The medical community will have hot takes within 24 hours of the presentation. Most of them will be too breathless in either direction. The honest read takes weeks and depends on how the full discussant slides land.
What “Triple Agonist” Actually Means
Single-mechanism (GLP-1): mimics the gut hormone that signals satiety and slows gastric emptying. This is semaglutide (Wegovy / Ozempic).
Dual-mechanism (GLP-1 + GIP): adds GIP receptor activation, which improves the metabolic response to nutrient intake. This is tirzepatide (Zepbound / Mounjaro).
Triple-mechanism (GLP-1 + GIP + glucagon): retatrutide. The glucagon-receptor activation increases energy expenditure — your body burns through fuel faster — on top of the satiety and metabolic-response signals.
What this means in clinical effect:
- Higher weight loss potential because three pathways are pulling at the same time
- Higher metabolic intensity, which carries higher tolerability tradeoffs (GI side effects, fatigue, fluid shifts)
- Different muscle-preservation profile that the Phase 3 data should clarify — this matters significantly for women, older patients, and athletes
For patients already on Zepbound who have hit a weight-loss plateau, retatrutide’s mechanism is one of the reasons they’re paying close attention.
FDA Approval Timeline (Realistic, Not Hype)
If the TRIUMPH-1 Phase 3 data holds, Lilly is positioned to file the New Drug Application in the second half of 2026. FDA review timelines for a drug of this profile typically run 10-12 months from submission. That puts the realistic approval window at late 2026 to mid-2027 for the obesity indication.
Insurance coverage will lag approval by 6-18 months as PBMs renegotiate formularies. Real-world supply at scale (no shortage) is likely mid-to-late 2027 at the earliest.
If you’re trying to decide whether to “wait for retatrutide,” that’s a 12-24 month wait under realistic assumptions — and the answer for most patients is that you can’t put your metabolic health on hold for 12-24 months.
The Honest Decision Framework
This is what I’d walk a patient through in the Tustin practice.
If you’re already on a GLP-1 and it’s working:
- Don’t switch anything based on retatrutide news. The current medication is producing results; the new option isn’t real for ~18 more months.
- Continue with what’s working. Re-evaluate when retatrutide actually becomes available and your prescriber can compare your real-world data on the current med against retatrutide’s profile.
- Do think about the muscle-preservation and rebound-prevention work that should layer on whatever GLP-1 you’re on. That work matters at the next-gen tier too.
If you’re on a GLP-1 and it’s not working well:
- The honest first move isn’t to wait for retatrutide. It’s to figure out what’s not working — dose, adherence, the surrounding protocol, the underlying metabolic picture.
- The functional-medicine workup picks up things the GLP-1 prescription pathway misses: thyroid function, cortisol patterns, gut microbiome status, insulin sensitivity beyond fasting glucose, food sensitivities driving inflammation, sleep architecture.
- For some patients, addressing the underlying picture is what unlocks the GLP-1 working better. For others, the protocol needs to change. For a few, GLP-1 wasn’t the right tool for them in the first place.
If you’ve never been on a GLP-1 but you’re considering one:
- Retatrutide news isn’t a reason to wait if you have a clinical case for starting now. Talk to your prescriber about which currently-available option fits you.
- Build the surrounding protocol before you start. Nutrition, muscle preservation, sleep, stress regulation, gut health all matter for whether GLP-1 produces lasting outcomes vs. a temporary weight loss with rebound.
- If you’re in Orange County, this is exactly the kind of protocol design the Tustin practice does.
If you’re researching weight loss generally and you’re not sure where to start:
- Start with comprehensive bloodwork. Function Health or a similar comprehensive panel gives you the metabolic picture.
- Address the foundational layers (sleep, stress, gut, hormones) before assuming pharmacology is the answer. For some people pharmacology is right; for others the foundational work alone produces meaningful results.
- If pharmacology turns out to be right for you, you’ll be a much better candidate for any GLP-1 — current or next-generation — because the surrounding work is already in place.
What Retatrutide Doesn’t Change
The medication is a tool. It is not a metabolic strategy. The patients who get durable outcomes on any GLP-1 — current or next-generation — share a pattern:
- They preserved muscle mass through structured resistance work
- They prioritized protein intake
- They got sleep architecture into a healthier range
- They addressed stress and cortisol regulation
- They worked on the gut microbiome that affects GLP-1 receptor sensitivity in the first place
- They had a plan for what happens at month 18, 24, 36 — not just the weight-loss phase
Retatrutide will be more potent. It will not change the structural reality that pharmacology without the surrounding protocol produces fast weight loss with significant rebound risk. The work around the medication is where durability lives.
What About Compounded Retatrutide
Currently, retatrutide is not commercially available in any form, including through 503A or 503B compounding pharmacies. Lilly holds the active ingredient. Any “compounded retatrutide” being marketed today is highly questionable — both legally and clinically. The FDA is actively enforcing on the broader compounded weight-loss space, and the framework will get tighter, not looser, as the next-gen drugs approach approval.
If you see a website offering “research-grade retatrutide” before the drug is approved, that’s not a serious medical option.
What This Means for the Broader Category
Retatrutide approval will reshape the GLP-1 category around 2027. Wegovy and Zepbound will not disappear — they’ll continue to serve patients who respond well at their efficacy tier. The clinical decision tree will get more nuanced: which mechanism profile fits which patient. Insurance coverage will become harder to navigate.
For functional medicine and clinician-led care, this raises the value of the surrounding work, not lowers it. More potent pharmacology with more aggressive side-effect profiles makes the protocol design matter more, not less.
Frequently Asked Questions
Will retatrutide be safer than Zepbound? Unknown until the full safety data is published and real-world data accumulates. More potent mechanism generally carries more tolerability tradeoffs. The Phase 3 safety profile is exactly what mid-June ADA will start to clarify.
Will retatrutide cost more than Zepbound? Probably yes at launch, given pricing patterns in the category. Long-term, prices come down as competition increases.
Will I lose more weight on retatrutide? Probably yes on average, given the Phase 2 data. Individual response varies significantly. The patients who respond best to any GLP-1 are the ones with the surrounding protocol in place.
Should I switch off my current GLP-1 to wait for retatrutide? No. The wait is 12-24 months. Continue what’s working, talk to your prescriber when retatrutide becomes available.
Will retatrutide be approved for kids/adolescents? The initial approval will be for adults. Pediatric indications follow standard pediatric trial pathways after adult approval.
Will Medicare cover retatrutide? Probably eventually for cardiometabolic conditions, on the same long timeline that Medicare coverage for Wegovy and Zepbound has followed.
Should I get bloodwork before considering any GLP-1? Yes. Comprehensive bloodwork (thyroid, insulin sensitivity beyond fasting glucose, inflammation markers, hormones, vitamin/mineral status) is the right first step before any metabolic intervention.
What to Do This Week
If you’re already on a GLP-1 and it’s working: stay the course. Watch the ADA news with curiosity, not anxiety.
If you’re on a GLP-1 and you’re not seeing the results you hoped for: stop optimizing the medication and start optimizing the surrounding protocol. The functional-medicine workup is the next move.
If you’re in Orange County and you want a real protocol design — not a fast Rx — book a first visit at the Tustin practice. $199 in-person initial, $150 virtual. Cash, HSA/FSA, and superbill for out-of-network insurance reimbursement.
If you want to track this category yourself, follow the ADA Scientific Sessions coverage from credible sources and watch how the safety subgroup analysis unfolds over the following weeks — that’s where the honest read lives.
Dr. Brandon Bright, DAOM, LAc
Holistic and integrative medicine practitioner serving Tustin and patients nationwide.